Together, these data suggest that in the mouse model of AOM/DSS-induced colon cancer, Crhr2 deficiency exacerbates tumorigenicity, while loss of Crhr1 does not seem to alter the intestinal tumor development and growth. This evidence concerns the gene CRHR2 and intestinal neoplasm.